Women receiving cardiac resynchronisation therapy with defibrillator (CRT-D) have greater reduction in heart failure than men, according to a new study.

The study, published in the Journal of the American College of Cardiology, revealed that women treated with CRT-D device experienced a 70% reduction in heart failure, compared to men who had 35% reduction, which indicates that women derive twice the benefit from the device.

In addition, in women with mild heart failure, CRT-D device effectively prevented deterioration of the heart, by preventing enlargement of the heart with more effective contraction of the heart.

The study used CRT-D device developed by Boston Scientific, which is approved to treat patients with mild to severe heart failure.

A CRT-D device combines implantable cardioverter defibrillator (ICD) which prevents sudden, rhythm-related cardiac death as well as cardiac resynchronisation therapy (CRT), which improves heart function.

According to the study authors, the study results can be attributed to the fact that women in the study were more likely to have non-ischemic heart disease, while men had a greater likelihood of having ischemic heart disease.